EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Stem Cell–Derived Organoids as a Next‐Generation Platform for Drug Toxicity and Efficacy Testing: Toward Replacing Animal Models in Regulatory Science

Sungmin Kim iD, Taeho Lee iD, Mingu Ryu iD, Yun-Gwi Park iD, Sung-Hwan Moon iD

Journal of Applied Toxicology · 2026-04 · 46 (4) · 1124-1146

DOI: 10.1002/jat.70059 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Applied Toxicology, online erschienen am 13.01.2026. Verfasst von Sungmin Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK. Hauptthemen laut MEDLINE: Organoids, Drug Evaluation, Preclinical, Toxicity Tests. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 243 Literaturangaben. Gefördert von: Chung-Ang University Graduate Research Scholarship 2023, Commercialization Promotion Agency for R&D Outcomes (COMPA), National Research Foundation (NRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Three‐dimensional, self‐organizing structures derived from stem cells, known as organoids, represent a groundbreaking advancement in preclinical drug development. Organoid‐based platforms advance preclinical testing by providing an accurate representation of human tissue architecture and genetics, surpassing traditional two‐dimensional cultures and animal models in testing both drug safety and efficacy. Researchers are shifting toward organoid‐based systems as primary components of new approach methodologies, as global regulatory bodies increasingly acknowledge animal testing limitations. This review delivers an exhaustive examination of organoid technologies and their applications in drug testing. Our study explores current methods used to model toxic responses in different organs—such as the liver, kidney, and heart—while highlighting how personalized and disease‐specific organoids can enhance the accuracy of efficacy testing. Our investigation also examines regulatory frameworks and outlines the path toward organoid platform standardization and validation before their integration into drug development processes. Complex neural organoids show great promise but continue to face significant challenges, including biological variability, a lack of universal standards, and ethical concerns. The combination of organoid technology with microengineering techniques, artificial intelligence–based analysis, and high‐throughput screening methods represents a transformative change in translational medicine. Organoid‐based systems represent both scientific breakthroughs and ethical necessities, as they provide human‐specific data while reducing dependence on animal testing. If organoid development progresses with regulatory approval, it could fundamentally transform drug discovery and safety evaluation methods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrganoidsDrug Evaluation, PreclinicalToxicity TestsHumansAnimalsAnimal Testing AlternativesStem CellsModels, Animal

Stichwörter der Autor:innen

animal‐free modelsdrug efficacy assessmentorganoidsregulatory sciencetoxicity testing

Autor:innen und Institutionen

  • School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
  • Department of Animal Science and Technology, College of Biotechnology and Natural Resources, Chung-Ang University, Anseong, Republic of Korea.

ORCID-Profile: Sungmin Kim, Taeho Lee, Mingu Ryu, Yun-Gwi Park, Sung-Hwan Moon

Förderung

  • Chung-Ang University Graduate Research Scholarship 2023
  • Commercialization Promotion Agency for R&D Outcomes (COMPA)
  • National Research Foundation (NRF)

Zitieren

APA

Kim, S., Lee, T., Ryu, M., Park, Y. G., & Moon, S. H. (2026). Stem Cell–Derived Organoids as a Next‐Generation Platform for Drug Toxicity and Efficacy Testing: Toward Replacing Animal Models in Regulatory Science. Journal of Applied Toxicology, 46(4), 1124-1146. https://doi.org/10.1002/jat.70059

Vancouver

Kim S, Lee T, Ryu M, Park YG, Moon SH. Stem Cell–Derived Organoids as a Next‐Generation Platform for Drug Toxicity and Efficacy Testing: Toward Replacing Animal Models in Regulatory Science. Journal of Applied Toxicology. 2026;46(4):1124-1146. doi:10.1002/jat.70059

BibTeX
@article{Kim2026,
  author = {Kim, Sungmin and Lee, Taeho and Ryu, Mingu and Park, Yun-Gwi and Moon, Sung-Hwan},
  title = {Stem Cell–Derived Organoids as a Next‐Generation Platform for Drug Toxicity and Efficacy Testing: Toward Replacing Animal Models in Regulatory Science},
  journal = {Journal of Applied Toxicology},
  year = {2026},
  volume = {46},
  number = {4},
  pages = {1124--1146},
  doi = {10.1002/jat.70059}
}
Kostenlos starten →